<DOC>
	<DOCNO>NCT02141061</DOCNO>
	<brief_summary>This study double-blind crossover study female healthy volunteer compare pharmacokinetics safety single dose two different formulation Proellex oral administration . Each formulation designate either Treatment A Treatment B . A total 12 subject meet eligibility criterion randomize receive either Treatment A Treatment B first assign treatment . After 7-day washout period subject receive alternative treatment . On day treatment subject remain clinic overnight undergo 72-hour pharmacokinetic assessment follow time point : 0 , 0.5 , 1 , 2 , 3 , 4 , 8 , 12 , 16 , 24 , 48 72 hour administration study drug .</brief_summary>
	<brief_title>Comparison Two Formulations Proellex Oral Administration</brief_title>
	<detailed_description />
	<criteria>1 . Speak , read , understand English Spanish willing able provide write informed consent IRBapproved form prior initiation study procedure ; 2 . Healthy , premenopausal female age 1847 ; 3 . History menstrual event occur regular cycle 4 . Agreement attempt become pregnant 5 . Agrees use doublebarrier contraception study 30 day discontinuation study medication . Acceptable doublebarrier method : male condom spermicide ; male condom diaphragm ; diaphragm contain spermicide plus additional intravaginal spermicide ; 6 . Has negative pregnancy test Screening visit . An exception pregnancy test requirement grant subject report surgical sterilization medical history 7 . Normal laboratory value clinically insignificant finding screen determined Investigator ; 8 . Subject willing remain clinic overnight PK assessment Days 0 8 9 . Ability complete study procedure compliance protocol . 1 . Subject postmenopausal woman , define either ; six ( 6 ) month ( immediately prior screen visit ) without menstrual period , prior hysterectomy and/or oophorectomy 2 . Subject pregnant lactating attempt expect become pregnant study 3 . Women abnormally high liver enzymes liver disease . ( ALT AST exceed 2.0 x ULN AND total bilirubin exceed 1.5 x ULN screening confirm repeat ) . 4 . Received investigational drug 30 day prior screen study 5 . Women history PCOS 6 . Concurrent use testosterone , progestin , androgen , estrogen , anabolic steroid , DHEA hormonal product least 2 week prior screen study . 7 . Use oral contraceptive precede 2 week . Use DepoProveraÂ® precede 10 month . 8 . Has IUD place 9 . Women currently use narcotic 10 . Women currently take spironolactone 11 . Infectious disease screen positive HIV Hepatitis A , B C. 12 . Clinically significant abnormal finding screen examination condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>